Cogent Biosciences Inc (COGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,833 | -34,532 | -25,492 | -18,124 | -6,592 |
| Depreciation Amortization | 1,240 | 1,075 | 1,188 | 847 | 179 |
| Accounts receivable | -332 | -838 | 98 | -634 | -294 |
| Accounts payable and accrued liabilities | 1,664 | 367 | -31 | 389 | 705 |
| Other Working Capital | -15,449 | -2,153 | -2,879 | -2,323 | 23,881 |
| Other Operating Activity | 3,196 | 3,592 | 1,281 | 1,205 | -163 |
| Operating Cash Flow | $-41,514 | $-32,489 | $-25,835 | $-18,640 | $17,716 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 171 | -549 | -912 | -3,307 | -1,994 |
| Purchase Of Investment | N/A | -47,682 | -6,500 | -55,172 | N/A |
| Sale Of Investment | 22,988 | 37,700 | 21,000 | 28,000 | N/A |
| Other Investing Activity | 0 | 0 | 0 | 50 | -1,255 |
| Investing Cash Flow | $23,159 | $-10,531 | $13,588 | $-30,429 | $-3,249 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 108 | 67,402 | 60 | N/A | N/A |
| Other Financing Activity | 0 | 2,944 | -789 | -40 | 70,752 |
| Financing Cash Flow | $108 | $70,346 | $-729 | $-40 | $70,752 |
| Beginning Cash Position | 56,926 | 29,600 | 42,576 | 90,430 | 5,211 |
| End Cash Position | 38,679 | 56,926 | 29,600 | 41,321 | 90,430 |
| Net Cash Flow | $-18,247 | $27,326 | $-12,976 | $-49,109 | $85,219 |
| Free Cash Flow | |||||
| Operating Cash Flow | -41,514 | -32,489 | -25,835 | -18,640 | 17,716 |
| Capital Expenditure | -33 | -549 | -912 | -3,307 | -1,994 |
| Free Cash Flow | -41,547 | -33,038 | -26,747 | -21,947 | 15,722 |